The KANK1 Knockout HT29 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population derived from the HT29 human colorectal adenocarcinoma cell line, offering a heterogeneous loss-of-function model for studying KANK1 gene disruption. This polyclonal format enriches diverse editing events, ensuring broad representation of knockout phenotypes and minimizing clonal artifacts. The cells provide a versatile platform for dissecting KANK1??s role in actin dynamics, adhesion, and tumor suppression.
The parental HT29 cell line, established from a primary colorectal adenocarcinoma of a 44-year-old female, is a classic model for intestinal epithelial biology. These cells produce mucin, form polarized monolayers with tight junctions, and differentiate under serum-depleted conditions, recapitulating features of the colonic epithelium. Their wild-type p53 status and ability to undergo enterocytic differentiation make them relevant for colorectal cancer, barrier function, and DNA damage response studies.
KANK1 functions as a scaffold protein that coordinates integrin-mediated adhesion with actin cytoskeletal regulation. It recruits talin and ??-parvin to focal adhesions, leading to inhibition of RhoA-ROCK signaling and suppression of stress fiber formation. KANK1 activity is governed by integrin binding and mechanical cues, while its expression is upregulated by TGF-?? via EGR1. Downstream, it modulates cofilin phosphorylation through LIMK and promotes E-cadherin stability at adherens junctions. Interactions with liprin-??1 and KIF21A connect adhesion sites to microtubule networks. In specialized contexts such as podocytes, KANK1 regulates DIAPH1 (mDia1) to maintain the glomerular filtration barrier, linking its dysfunction to steroid-resistant nephrotic syndrome.
In the HT29 context, KANK1 knockout disrupts the delicate balance between adhesion and contractility, leading to elevated RhoA activity and increased actin stress fiber assembly. This results in weakened cell-cell contacts, enhanced migratory and invasive behavior, and altered proliferation??hallmarks of colorectal cancer progression. The polyclonal nature of this knockout population mirrors tumor heterogeneity, facilitating studies on clonal variation, drug sensitivity, and metastatic potential. Moreover, the HT29 differentiation capacity allows assessment of KANK1??s impact on mucin secretion and epithelial polarization.
Research applications encompass molecular, cellular, and functional assays. Western blotting can quantify changes in KANK1, RhoA, and phospho-cofilin, while immunofluorescence visualizes F-actin reorganization and vinculin distribution. Functional assays such as Transwell migration/invasion and adhesion assays directly measure metastatic capacity. RhoA activity pulldown (G-LISA) and RNA-seq transcriptomic profiling provide mechanistic insights into pathway dysregulation. Proliferation assays (EdU, MTT) and cell cycle analysis further characterize growth alterations. Additional avenues include investigation of Hippo/TAZ pathway crosstalk and podocyte biology for renal disease modeling. For technical support or ordering details, please contact Ascent Research.
